Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2013 Sep 15;19(18):5227-39. doi: 10.1158/1078-0432.CCR-13-0489. Epub 2013 Aug 9.

3.

Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.

Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS.

Int J Gynecol Cancer. 2013 Sep;23(7):1219-25. doi: 10.1097/IGC.0b013e31829f17c9.

PMID:
23975042
4.

Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.

Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA.

Int J Gynecol Cancer. 2012 May;22(4):566-72. doi: 10.1097/IGC.0b013e318247727f.

PMID:
22426404
5.

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O.

Int J Gynecol Cancer. 2015 May;25(4):599-606. doi: 10.1097/IGC.0000000000000389.

6.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
7.

Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.

Safra T, Berman T, Yachnin A, Bruchim I, Meirovitz M, Barak F, Atlas I, Levy T, Rosengarten OS.

Int J Gynecol Cancer. 2013 Mar;23(3):475-80. doi: 10.1097/IGC.0b013e3182866944.

PMID:
23435437
8.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28.

PMID:
23296063
9.

What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?

Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ.

J Chemother. 2009 Nov;21(5):566-72.

PMID:
19933049
10.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

11.

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR.

Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27.

12.

Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.

Gąsowska-Bodnar A, Bodnar L, Dąbek A, Cichowicz M, Jerzak M, Cierniak S, Kozłowski W, Baranowski W.

Int J Gynecol Cancer. 2014 May;24(4):687-96. doi: 10.1097/IGC.0000000000000108.

PMID:
24662134
13.

Biomarkers and response to bevacizumab--letter.

Cremolini C, Loupakis F, Bocci G, Falcone A.

Clin Cancer Res. 2014 Feb 15;20(4):1056-7. doi: 10.1158/1078-0432.CCR-13-2763. No abstract available.

14.

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.

Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C.

Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190.

15.
16.
17.

Biomarkers and response to bevacizumab--response.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269. No abstract available.

18.

Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.

Chang SJ, Bristow RE, Ryu HS.

Ann Surg Oncol. 2012 Dec;19(13):4059-67. doi: 10.1245/s10434-012-2446-8. Epub 2012 Jul 6.

PMID:
22766983
19.

CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC Jr, Liu J.

Int J Gynecol Cancer. 2013 Jun;23(5):815-22. doi: 10.1097/IGC.0b013e31828f7a24.

20.

Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.

Pylväs M, Puistola U, Laatio L, Kauppila S, Karihtala P.

Anticancer Res. 2011 Apr;31(4):1411-5.

PMID:
21508394
Items per page

Supplemental Content

Write to the Help Desk